BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21893148)

  • 1. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.
    Williams SE; Pahud BA; Vellozzi C; Donofrio PD; Dekker CL; Halsey N; Klein NP; Baxter RP; Marchant CD; Larussa PS; Barnett ED; Tokars JI; McGeeney BE; Sparks RC; Aukes LL; Jakob K; Coronel S; Sejvar JJ; Slade BA; Edwards KM
    Vaccine; 2011 Oct; 29(46):8302-8. PubMed ID: 21893148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination.
    Pahud BA; Williams SE; Dekker CL; Halsey N; Larussa P; Baxter RP; Klein NP; Marchant CD; Sparks RC; Jakob K; Aukes L; Swope S; Barnett E; Lewis P; Berger M; Dreskin SC; Donofrio PD; Sejvar JJ; Slade BA; Gidudu J; Vellozzi C; Edwards KM
    Pediatr Infect Dis J; 2013 Feb; 32(2):163-8. PubMed ID: 23334340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.
    Ropero-Álvarez AM; Whittembury A; Bravo-Alcántara P; Kurtis HJ; Danovaro-Holliday MC; Velandia-González M
    Vaccine; 2015 Jan; 33(1):187-92. PubMed ID: 25444798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
    Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
    Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guillain-Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition.
    Choe YJ; Cho H; Bae GR; Lee JK
    Vaccine; 2011 Mar; 29(11):2066-70. PubMed ID: 21255684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.
    Isai A; Durand J; Le Meur S; Hidalgo-Simon A; Kurz X
    Vaccine; 2012 Nov; 30(49):7123-9. PubMed ID: 23022149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
    Salmon DA; Proschan M; Forshee R; Gargiullo P; Bleser W; Burwen DR; Cunningham F; Garman P; Greene SK; Lee GM; Vellozzi C; Yih WK; Gellin B; Lurie N;
    Lancet; 2013 Apr; 381(9876):1461-8. PubMed ID: 23498095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
    Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
    Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series.
    Andrews N; Stowe J; Al-Shahi Salman R; Miller E
    Vaccine; 2011 Oct; 29(45):7878-82. PubMed ID: 21875631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Loughlin AM; Marchant CD; Adams W; Barnett E; Baxter R; Black S; Casey C; Dekker C; Edwards KM; Klein J; Klein NP; LaRussa P; Sparks R; Jakob K
    Vaccine; 2012 Nov; 30(50):7253-9. PubMed ID: 23063829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.
    Dodd CN; Romio SA; Black S; Vellozzi C; Andrews N; Sturkenboom M; Zuber P; Hua W; Bonhoeffer J; Buttery J; Crawford N; Deceuninck G; de Vries C; De Wals P; Gutierrez-Gimeno MV; Heijbel H; Hughes H; Hur K; Hviid A; Kelman J; Kilpi T; Chuang SK; Macartney K; Rett M; Lopez-Callada VR; Salmon D; Gimenez-Sanchez F; Sanz N; Silverman B; Storsaeter J; Thirugnanam U; van der Maas N; Yih K; Zhang T; Izurieta H;
    Vaccine; 2013 Sep; 31(40):4448-58. PubMed ID: 23770307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barré syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA Vaccine Adverse Event Reporting System (2009).
    Souayah N; Yacoub HA; Khan HM; Michas-Martin PA; Menkes DL; Maybodi L; Qureshi AI
    Neuroepidemiology; 2012; 38(4):227-32. PubMed ID: 22555646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010.
    Yih WK; Lee GM; Lieu TA; Ball R; Kulldorff M; Rett M; Wahl PM; McMahill-Walraven CN; Platt R; Salmon DA
    Am J Epidemiol; 2012 Jun; 175(11):1120-8. PubMed ID: 22582207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
    Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M
    Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting?
    McNeil MM; Arana J; Stewart B; Hartshorn M; Hrncir D; Wang H; Lamias M; Locke M; Stamper J; Tokars JI; Engler RJ
    Vaccine; 2012 Mar; 30(14):2421-6. PubMed ID: 22310205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.